170 related articles for article (PubMed ID: 36517481)
1. Cancer Immunology: Immune Escape of Tumors-Expression and Regulation of HLA Class I Molecules and Its Role in Immunotherapies.
Wang Y; Jasinski-Bergner S; Wickenhauser C; Seliger B
Adv Anat Pathol; 2023 May; 30(3):148-159. PubMed ID: 36517481
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
Seliger B
HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
[TBL] [Abstract][Full Text] [Related]
3. HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
Seliger B; Ferrone S
Methods Mol Biol; 2020; 2055():325-350. PubMed ID: 31502159
[TBL] [Abstract][Full Text] [Related]
4. Role of altered expression of HLA class I molecules in cancer progression.
Aptsiauri N; Cabrera T; Mendez R; Garcia-Lora A; Ruiz-Cabello F; Garrido F
Adv Exp Med Biol; 2007; 601():123-31. PubMed ID: 17712999
[TBL] [Abstract][Full Text] [Related]
5. Targeting HLA class I expression to increase tumor immunogenicity.
del Campo AB; Carretero J; Aptsiauri N; Garrido F
Tissue Antigens; 2012 Mar; 79(3):147-54. PubMed ID: 22309256
[TBL] [Abstract][Full Text] [Related]
6. Cancer immune escape: MHC expression in primary tumours versus metastases.
Garrido F; Aptsiauri N
Immunology; 2019 Dec; 158(4):255-266. PubMed ID: 31509607
[TBL] [Abstract][Full Text] [Related]
7. The role of classical and non-classical HLA class I antigens in human tumors.
Bukur J; Jasinski S; Seliger B
Semin Cancer Biol; 2012 Aug; 22(4):350-8. PubMed ID: 22465194
[TBL] [Abstract][Full Text] [Related]
8. Assessment of cancer cell-expressed HLA class I molecules and their immunopathological implications.
Kubo T; Asano S; Sasaki K; Murata K; Kanaseki T; Tsukahara T; Hirohashi Y; Torigoe T
HLA; 2024 May; 103(5):e15472. PubMed ID: 38699870
[TBL] [Abstract][Full Text] [Related]
9. The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes.
Aptsiauri N; Garrido F
Clin Cancer Res; 2022 Dec; 28(23):5021-5029. PubMed ID: 35861868
[TBL] [Abstract][Full Text] [Related]
10. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy.
Maggs L; Sadagopan A; Moghaddam AS; Ferrone S
Trends Cancer; 2021 Dec; 7(12):1089-1101. PubMed ID: 34489208
[TBL] [Abstract][Full Text] [Related]
11. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.
Anderson P; Aptsiauri N; Ruiz-Cabello F; Garrido F
Cell Mol Immunol; 2021 Mar; 18(3):556-565. PubMed ID: 33473191
[TBL] [Abstract][Full Text] [Related]
12. The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses.
Aptsiauri N; Ruiz-Cabello F; Garrido F
Curr Opin Immunol; 2018 Apr; 51():123-132. PubMed ID: 29567511
[TBL] [Abstract][Full Text] [Related]
13. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
Aptsiauri N; Carretero R; Garcia-Lora A; Real LM; Cabrera T; Garrido F
Cancer Immunol Immunother; 2008 Nov; 57(11):1727-33. PubMed ID: 18491093
[TBL] [Abstract][Full Text] [Related]
14. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
Marijt KA; Doorduijn EM; van Hall T
Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
[TBL] [Abstract][Full Text] [Related]
15. HLA class I defects in malignant lesions: what have we learned?
Chang CC; Campoli M; Ferrone S
Keio J Med; 2003 Dec; 52(4):220-9. PubMed ID: 14748474
[TBL] [Abstract][Full Text] [Related]
16. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy.
Friedrich M; Jasinski-Bergner S; Lazaridou MF; Subbarayan K; Massa C; Tretbar S; Mueller A; Handke D; Biehl K; Bukur J; Donia M; Mandelboim O; Seliger B
Cancer Immunol Immunother; 2019 Oct; 68(10):1689-1700. PubMed ID: 31375885
[TBL] [Abstract][Full Text] [Related]
17. The HLA crossroad in tumor immunology.
Algarra I; Cabrera T; Garrido F
Hum Immunol; 2000 Jan; 61(1):65-73. PubMed ID: 10658979
[TBL] [Abstract][Full Text] [Related]
18. Mismatch Repair Protein Deficiency Is a Risk Factor for Aberrant Expression of HLA Class I Molecules: A Putative "Adaptive Immune Escape" Phenomenon.
Kubo T; Hirohashi Y; Matsuo K; Sonoda T; Sakamoto H; Furumura K; Tsukahara T; Kanaseki T; Nakatsugawa M; Hirano H; Furuhata T; Takemasa I; Hasegawa T; Torigoe T
Anticancer Res; 2017 Mar; 37(3):1289-1295. PubMed ID: 28314294
[TBL] [Abstract][Full Text] [Related]
19. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
20. MHC heterogeneity and response of metastases to immunotherapy.
Algarra I; Garrido F; Garcia-Lora AM
Cancer Metastasis Rev; 2021 Jun; 40(2):501-517. PubMed ID: 33860434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
